(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.34%) $0.935
(0.56%) $11.01
(0.16%) $0.801
(0.00%) $92.17
4 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.47%
@ $8.24
Utstedt: 14 feb 2024 @ 21:41
Avkastning: -36.13%
Forrige signal: feb 13 - 21:50
Forrige signal:
Avkastning: 3.45 %
Live Chart Being Loaded With Signals
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases...
Stats | |
---|---|
Dagens volum | 1.22M |
Gjennomsnittsvolum | 1.21M |
Markedsverdi | 400.28M |
EPS | $0 ( 2024-02-15 ) |
Neste inntjeningsdato | ( $-0.950 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.00800 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Cline Christopher R. | Sell | 54 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 135 000 | Common Stock |
2024-02-01 | Dube Eric M | Sell | 9 106 | Common Stock |
2024-01-31 | Dube Eric M | Buy | 360 000 | Employee stock option (right to buy) |
2024-02-01 | Dube Eric M | Sell | 10 016 | Common Stock |
INSIDER POWER |
---|
89.25 |
Last 100 transactions |
Buy: 2 015 500 | Sell: 106 721 |
Volum Korrelasjon
Travere Therapeutics, Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Travere Therapeutics, Korrelasjon - Valuta/Råvare
Travere Therapeutics, Økonomi
Annual | 2023 |
Omsetning: | $145.24M |
Bruttogevinst: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2023 |
Omsetning: | $145.24M |
Bruttogevinst: | $88.86M (61.18 %) |
EPS: | $-1.500 |
FY | 2022 |
Omsetning: | $212.02M |
Bruttogevinst: | $204.43M (96.42 %) |
EPS: | $-4.37 |
FY | 2021 |
Omsetning: | $227.49M |
Bruttogevinst: | $220.71M (97.02 %) |
EPS: | $-3.79 |
Financial Reports:
No articles found.
Travere Therapeutics,
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.